Molbio Diagnostics IPO: ₹980 Debut, ₹940 Cr Raised for Global Growth

Molbio Diagnostics commenced trading on the stock market at ₹980 per share, achieving a substantial 21% premium over its initial issue price of ₹807. This successful debut followed the company’s initial public offering, which secured approximately ₹940 crore in capital.

Strategic Capital Allocation

The significant funds raised from the IPO are precisely earmarked for two core areas of investment. These initiatives are central to bolstering the company’s operational capabilities and innovation pipeline.

• Establishment of a brand-new, state-of-the-art R&D facility.
• Enhancement of existing manufacturing processes through advanced automation.

Global and Platform Expansion

Beyond internal infrastructure, Molbio Diagnostics is also executing an ambitious global and product diversification strategy. This involves a multi-pronged approach to extend its market reach and technological offerings.

• Expanding its global footprint, targeting entry into developed markets like the US and Europe.
• Broadening the application of its Truenat diagnostics platform to encompass new disease areas.
• Actively exploring additional international business opportunities to drive growth.
• Making advancements in the field of digital pathology to enhance diagnostic capabilities.
• Venturing into the specialized sector of veterinary diagnostics.

Sriram Natarajan, who serves as the CEO of Molbio Diagnostics, detailed these strategic post-IPO growth initiatives during an interview with Business Today TV. He specifically outlined the company’s future direction, emphasizing the expansion of its Truenat platform and its broader diversification efforts across new segments.